Anupam Rasayan Reports Q2FY22 Results
Total Revenue of ₹2,552 Mn; growth of 7% YoY Profit After Tax at ₹502 Mn; growth of 37%
Surat : Anupam Rasayan India Ltd. (BSE- 543275, NSE- ANURAS, ISIN: INE930P01018), one of India’s leading custom synthesis and specialty chemical player, has announced its financial results for the quarter and half year ended September 30, 2021.
Financial Highlights for Second Quarter Ended September 30th, 2021:
* Total Revenues at ₹2,552 million in Q2FY22 as compared to ₹2,390 million in Q2FY21 – growth of 7% Y-o-Y.
* EBITDA (incl. other revenue) at ₹702 million in Q2FY22 as compared to ₹636 million in Q2FY21 – growth of 10% Y-o-Y.
* Profit After Tax at ₹361 million in Q2FY22 as compared to ₹263 million in Q2FY21 – growth of 37% Y-o-Y.
* Total debt of ₹ 5,630 Mn repaid as of Q2FY22 from IPO proceeds
Financial Highlights for First Half Year Ended September 30th, 2021:
* Total Revenues at ₹4,931 million in H1FY22 as compared to ₹3,736 million in H1FY21 – growth of 32% Y-o-Y.
* EBITDA (incl. other revenue) at ₹1,352 million in H1FY22 as compared to ₹959 million in H1FY21 – growth of 41% Y-o-Y.
* Profit After Tax at ₹682 million in H1FY22 as compared to ₹265 million in H1FY21 – growth of 157% Y-o-Y.
Anand Desai, Managing Director of Anupam Rasayan, commented, “Continuing the momentum further, I am pleased to announce that we have delivered yet another quarter and half year of increased profitability and strengthening balance sheet. Our margins along with metrics like client and geographic concentration have seen improvement even in midst of global raw material prices rising- due to our inventory policy and cost-plus model. Our new molecule launches, new export orders, achievement of further debt reduction targets and commissioning of solar plant in Bharuch will give further impetus to our margins going forward. The prudent financial and capital rationing technique that we are sticking to is also helping us deliver sustained growth.”
To Read Complete Report & Disclaimer Click Here
Above views are of the author and not of the website kindly read disclaimer